AAPL 184.35 1.1134% MSFT 411.6876 2.364% GOOG 145.3444 1.0459% GOOGL 144.175 1.14% AMZN 174.33 3.4047% NVDA 784.65 16.2927% META 486.18 3.878% TSLA 197.565 1.435% TSM 129.25 3.1195% LLY 769.655 3.1834% V 283.785 2.5383% AVGO 1304.8 6.3017% JPM 183.325 1.3405% UNH 525.425 0.6619% NVO 124.57 3.01% WMT 175.35 0.9499% LVMUY 182.36 1.7066% XOM 104.775 -0.0715% LVMHF 909.7617 1.9427% MA 471.85 2.7884%

Halozyme Therapeutics Inc

Healthcare US HALO


Last update at 2024-02-22T20:51:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 248.92M 248.52M 129.30M -72.25100M -79.79300M
Minority interest - - - - -
Net income 202.13M 402.71M 129.09M -72.24000M -80.33000M
Selling general administrative 143.53M 50.32M 45.74M 77.25M 60.80M
Selling and marketing expenses - - - - -
Gross profit 520.81M 361.90M 224.23M 150.45M 141.73M
Reconciled depreciation 49.64M 3.00M 3.28M 4.07M 2.39M
Ebit 267.53M 272.90M 140.97M -71.67800M -71.71800M
Ebitda 310.68M 275.90M 144.25M -67.61000M -69.33000M
Depreciation and amortization 43.15M 3.00M 3.28M 4.07M 2.39M
Non operating income net other -1.66600M -19.85800M 5.42M 6.99M 7.58M
Operating income 267.53M 275.90M 144.25M -67.61000M -69.33000M
Other operating expenses 392.58M 167.41M 123.34M 263.60M 221.19M
Interest expense 16.95M 7.53M 20.38M 11.63M 18.04M
Tax provision 46.79M -154.19200M 0.22M -0.01100M 0.54M
Interest income - - - 4.64M 10.46M
Net interest income -16.94700M -7.52600M -20.37800M -11.62700M -18.04100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 46.79M -154.19200M 0.22M -0.01100M 0.54M
Total revenue 660.12M 443.31M 267.59M 195.99M 151.86M
Total operating expenses 253.28M 86.00M 79.97M 218.06M 211.06M
Cost of revenue 139.30M 81.41M 43.37M 45.55M 10.14M
Total other income expense net -18.61300M -27.38400M -14.95300M -4.64100M 7.58M
Discontinued operations - - - - -
Net income from continuing ops 202.13M 402.71M 129.09M -72.24000M -80.33000M
Net income applicable to common shares 202.13M 402.71M 129.09M -72.24000M -80.33000M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1841.51M 1104.43M 579.92M 565.87M 440.25M
Intangible assets 546.65M - - - -
Earning assets - - - - -
Other current assets 45.02M 40.48M 28.27M 33.37M 20.69M
Total liab 1671.71M 907.48M 428.88M 474.11M 191.36M
Total stockholder equity 169.80M 196.95M 151.05M 91.77M 248.89M
Deferred long term liab - - - 2.49M 5.01M
Other current liab 96.52M 24.44M 20.48M 55.65M 49.53M
Common stock 0.14M 0.14M 0.14M 0.14M 0.14M
Capital stock 0.14M 0.14M 0.14M 0.14M 0.14M
Retained earnings 143.22M -58.91200M -474.59300M -603.67800M -531.43800M
Other liab 17.73M 3.07M 7.49M 2.31M 7.13M
Good will 409.05M - - - -
Other assets 71.23M 169.35M 14.57M 11.58M 4.93M
Cash 234.19M 118.72M 147.70M 120.18M 57.94M
Cash and equivalents - - - - -
Total current liabilities 130.79M 117.15M 421.38M 85.64M 149.36M
Current deferred revenue 3.25M 1.75M 1.75M 4.01M 4.25M
Net debt 1271.90M 757.96M 249.53M 282.41M 68.44M
Short term debt 13.33M 89.42M 397.23M 19.54M 91.51M
Short long term debt 13.33M 89.42M 397.23M 19.54M 91.51M
Short long term debt total 1506.10M 876.67M 397.23M 402.59M 126.38M
Other stockholder equity 27.37M 256.35M 625.48M 695.07M 780.46M
Property plant equipment 75.57M 8.79M 10.59M 10.86M 7.46M
Total current assets 739.01M 926.29M 554.76M 543.44M 427.85M
Long term investments - - - - -
Net tangible assets -783.65000M 196.95M 155.07M 90.52M 248.89M
Short term investments 128.60M 622.20M 220.31M 301.08M 296.59M
Net receivables 231.07M 90.97M 97.73M 59.44M 30.00M
Long term debt 1492.77M 787.25M - 383.05M 34.87M
Inventory 100.12M 53.91M 60.75M 29.36M 22.62M
Accounts payable 17.69M 1.54M 1.93M 6.43M 4.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.92200M -0.62000M 0.02M 0.24M -0.27700M
Additional paid in capital - - - - -
Common stock total equity 0.14M 0.14M 0.14M 0.14M 0.14M
Preferred stock total equity - - - - -
Retained earnings total equity 143.22M -58.91200M -474.59300M -603.67800M -531.43800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 26.80M 13.91M 14.57M 11.58M 4.93M
Deferred long term asset charges - - - - -
Non current assets total 1102.50M 178.14M 25.16M 22.44M 12.40M
Capital lease obligations - - - - -
Long term debt total 1492.77M 787.25M - 383.05M 34.87M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 490.92M -404.83200M 79.78M -1.50900M 7.16M
Change to liabilities 24.54M 1.17M -36.57600M 4.64M 8.70M
Total cashflows from investing activities -487.00500M -406.28900M 78.35M -5.54900M 2.49M
Net borrowings 617.44M 415.81M -19.56000M 338.99M -77.51600M
Total cash from financing activities 362.37M 77.86M -106.28400M 153.22M -63.79700M
Change to operating activities -9.06400M -11.55500M 2.52M -19.00600M -5.69500M
Net income 202.13M 402.71M 129.09M -72.24000M -80.33000M
Change in cash 115.48M -28.98400M 27.52M 62.24M -110.80400M
Begin period cash flow 119.22M 148.20M 120.68M 58.44M 169.24M
End period cash flow 234.69M 119.22M 148.20M 120.68M 58.44M
Total cash from operating activities 240.11M 299.44M 55.45M -85.42300M -49.50000M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 49.64M 3.00M 3.28M 4.07M 2.39M
Other cashflows from investing activities -973.11400M - 1.08M -1.50900M 7.16M
Dividends paid - -12.53600M -63.39300M -14.22400M -
Change to inventory -17.48100M 7.37M -31.38800M -6.73400M -17.48000M
Change to account receivables -83.94100M 6.75M -38.28800M -29.43700M 11.61M
Sale purchase of stock -200.00200M -350.05800M -150.11700M -199.99800M 13.72M
Other cashflows from financing activities 995.78M 796.99M 63.39M 461.30M 2.49M
Change to netincome 67.02M -113.64700M 16.42M 36.14M 35.69M
Capital expenditures 4.81M 1.46M 2.50M 4.04M 4.66M
Change receivables -83.94100M 6.75M -38.28800M -29.43700M 11.61M
Cash flows other operating -10.73400M -13.80200M -2.05700M -17.87900M -5.69500M
Exchange rate changes - - - - -
Cash and cash equivalents changes 115.48M -28.98400M 27.52M 62.24M -110.80400M
Change in working capital -85.95100M 3.74M -108.36600M -50.53900M -5.86600M
Stock based compensation 24.40M 20.82M 17.20M 34.78M 35.70M
Other non cash items 9.89M 24.61M 13.60M -1.97800M 1.70M
Free cash flow 235.30M 297.98M 52.95M -89.46300M -54.16300M


  • Previous Close 38.36
  • Market Cap5125.40M
  • Volume1219936
  • P/E Ratio20.75
  • Dividend Yield3.06%
  • EBITDA396.22M
  • Revenue TTM780.71M
  • Revenue Per Share TTM5.85
  • Gross Profit TTM 454.20M
  • Diluted EPS TTM1.87

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Halozyme Therapeutics Inc
1.37 3.57% 39.73 20.75 9.49 6.57 20.57 7.94 15.81
Novo Nordisk A/S
3.64 3.01% 124.57 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
5.12 4.29% 124.40 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
7.83 1.87% 427.46 30.40 24.75 10.68 6.25 9.52 20.36
1.03 1.11% 93.74 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News


Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Halozyme Therapeutics Inc

11388 Sorrento Valley Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. Pres, CEO & Director 1963
Dr. Michael J. LaBarre Ph.D. Chief Technical Officer 1964
Ms. Nicole LaBrosse CFO & Director 1983
Ms. Tram Bui VP of Investor Relations & Corp. Communications NA
Mr. Mark Snyder Esq. Gen. Counsel, Chief Compliance Officer & Corp. Sec. NA
Ms. Amy Marinne Fox Chief HR Officer NA
Dr. Steve Knowles MBBS Chief Medical Officer NA
Mr. Todd Butler Chief of Staff to the CEO, VP & Head of Project Management NA
Dr. Christopher Bryant Ph.D. Chief Manufacturing Officer & Head of Technical Operations 1961

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).